Marina Vilaseca
Publicaciones destacadas
-
Advances in therapeutic options for portal hypertension
Autores:Referencia: Therapeutic Advances In Gastroenterology 2018. -
Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension.
Autores:Referencia: Gastroenterology 2018. -
Mitochondria-targeted antioxidant mitoquinone deactivates human and rat HSC and reduces portal hypertension in cirrhotic rats.
Autores:Referencia: Liver International 2017. -
The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells
Autores:Referencia: Hepatology 2017. -
Role of Oxidative Stress in Portal Hypertension in Cirrhosis
Autores:Referencia: GASTROINTESTINAL TISSUE: OXIDATIVE STRESS AND DIETARY ANTIOXIDANTS 2017. -
Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats
Autores:Referencia: Journal Of Hepatology 2016. -
RIVAROXABAN REDUCES PORTAL HYPERTENSION IN CIRRHOTIC RATS BY DEACTIVATING HEPATIC STELLATE CELLS AND REDUCING INTRAHEPATIC MICROTHROMBOSIS
Autores:Referencia: JOURNAL OF HEPATOLOGY 2016. -
Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats
Autores:Referencia: JOURNAL OF HEPATOLOGY 2013.